New York, May 23, 2026, 18:12 (EDT)
NovoCure shares climbed 0.3% Friday, closing the week at $17.96, up 2.2% from last Friday. After the bell, the stock fell to $17.71, with moves more volatile as volume dropped.
Small move, but the timing stands out. NovoCure shares are holding around 50% higher than where they closed on April 29, right before the cancer device maker posted Q1 numbers and hiked its 2026 revenue forecast.
Nasdaq will be closed Monday, May 25, for Memorial Day. The next regular session in the U.S. is Tuesday. Standard hours for Nasdaq are 9:30 a.m. to 4 p.m. Eastern.
NovoCure traded choppy last week. Shares dropped Monday and Tuesday, then gained 4.4% Wednesday and kept rising, though more slowly, Thursday and Friday. The stock closed just under $18, close to its 52-week high of $20.06, and still up sharply from late April.
The stock picked up after NovoCure’s April 30 report. First-quarter net revenue was $174.1 million, up 12% from a year ago, but the net loss grew to $71.1 million, or 62 cents a share. NovoCure bumped its 2026 revenue view to $690 million to $710 million, from an earlier range of $675 million to $705 million.
Chief Executive Frank Leonard said it was a “very strong start” and the company aims to “maintain this momentum” as it looks to hit more clinical and commercial milestones later in 2026. SEC
NovoCure sells Tumor Treating Fields (TTFields) therapy, using electric fields via wearable devices to try to stop cancer cell division. NovoCure said it had 4,791 active patients worldwide at the end of March. Of those, 4,543 were on Optune Gio for glioblastoma, 165 on Optune Lua, and 83 U.S. patients using the newly launched Optune Pax, which targets pancreatic cancer.
Analysts are paying closer attention to the new product rollouts than to the older brain-cancer line. Jonathan Chang at Leerink Partners pointed to the early Optune Pax launch data as “encouraging metrics,” with comments on prescriptions, patient starts and active patients, according to Investor’s Business Daily after the first-quarter numbers. Investors
NovoCure’s Optune Lua device is meant to fit alongside, not replace, existing drug regimens. The device has approval for use with PD-1/PD-L1 inhibitors or docetaxel in some metastatic non-small cell lung cancer cases. That puts Optune Lua on the same path as drugs like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo.
But adoption remains a big hurdle for the launch. Wedbush analyst David Nierengarten is still Neutral, flagging the challenge of daily device use and the actual survival improvement in pancreatic cancer. He wrote, “investors can be patient” as the market waits to see if doctors and patients are willing to adopt Optune Pax. Barron’s
NovoCure is on deck this week as investors wait for topline data from its Phase 3 TRIDENT trial in newly diagnosed glioblastoma, expected in the second quarter. The company is also looking for an FDA decision later in the year on TTFields for brain metastases tied to non-small cell lung cancer, plus it plans to finish enrollment in the KEYNOTE D58 glioblastoma study.
NovoCure shares are holding steady after a sharp repricing, with trading not set to resume until Tuesday. The task ahead is clear: keep momentum from the recent launch, avoid another stumble on losses, and put up results that back up the move.
